Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.

Autor: Lheureux, Stephanie1 (AUTHOR), Cristea, Mihaela C2 (AUTHOR), Bruce, Jeffrey P1 (AUTHOR), Garg, Swati1 (AUTHOR), Cabanero, Michael1 (AUTHOR), Mantia-Smaldone, Gina3 (AUTHOR), Olawaiye, Alexander B4 (AUTHOR), Ellard, Susan L5 (AUTHOR), Weberpals, Johanne I6 (AUTHOR), Wahner Hendrickson, Andrea E7 (AUTHOR), Fleming, Gini F8 (AUTHOR), Welch, Stephen9 (AUTHOR), Dhani, Neesha C1 (AUTHOR), Stockley, Tracy1 (AUTHOR), Rath, Prisni10 (AUTHOR), Karakasis, Katherine1 (AUTHOR), Jones, Gemma N11 (AUTHOR), Jenkins, Suzanne11 (AUTHOR), Rodriguez-Canales, Jaime11 (AUTHOR), Tracy, Michael11 (AUTHOR)
Zdroj: Lancet. 1/23/2021, Vol. 397 Issue 10271, p281-292. 12p.
Databáze: Academic Search Ultimate